61367-24-6 Usage
Uses
Used in Cancer Treatment:
Cyclophosphamide is used as a chemotherapeutic agent for the treatment of various types of cancer, including lymphoma, multiple myeloma, and certain types of leukemia. Its alkylating action interferes with the growth and spread of cancer cells, ultimately leading to cell death. It is particularly effective due to its ability to cross-link DNA, which disrupts the normal functioning of cancer cells and inhibits their proliferation.
Used in Combination Chemotherapy:
Cyclophosphamide is often used in combination with other chemotherapy medications to enhance the overall treatment efficacy. The synergistic effects of combining cyclophosphamide with other agents can lead to improved outcomes in cancer treatment, as it may help overcome resistance and increase the sensitivity of cancer cells to the therapeutic agents.
Used in Immunosuppression:
In addition to its cancer-treating properties, cyclophosphamide is also used as an immunosuppressive agent. Its ability to suppress the immune system makes it useful in the treatment of autoimmune diseases and in the prevention of organ transplant rejection.
Used in Pharmaceutical Industry:
Cyclophosphamide is a key component in the development of various pharmaceutical products, particularly in the field of oncology. Its unique properties and effectiveness against a range of cancers make it a valuable asset in the creation of new cancer treatments and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 61367-24-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,3,6 and 7 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 61367-24:
(7*6)+(6*1)+(5*3)+(4*6)+(3*7)+(2*2)+(1*4)=116
116 % 10 = 6
So 61367-24-6 is a valid CAS Registry Number.
61367-24-6Relevant academic research and scientific papers
Synthesis of analogues of N (2 chloroethyl) N' trans 4 methylcyclohexyl) N nitrosourea for evaluation as anticancer agents
Johnston,McCaleb,Clayton,Frye,Krauth,Montgomery
, p. 279 - 290 (2007/10/04)
The superior activity of N (2 chloroethyl) N' (trans 4 methylcyclohexyl) N nitrosourea (MeCCNU) against advanced murine Lewis lung carcinoma in comparisons with the cis form and other nitrosoureas prompted the synthesis of a number of MeCCNU analogues, including several cis trans pairs. The methyl group was replaced by a variety of substituents (CO2H, CH2CO2H, CO2Me, CH2OAc, CH2Cl, OMe); the trans 3 methylcyclohexyl, cis 2 methyl 1,3 dithian 5 yl, cis and trans 2 methyl 1,3 dithian 5 yl tetraoxide, and 1 methylhexyl (open chain) analogues were also prepared. Preliminary tests against murine leukemia L1210 revealed therapeutic indices (ED50/LD10) ranging from 0.26 to 0.79; all but 3 analogues effected 50% cure rates at nontoxic doses, the open chain analogue being one of the least active. In terms of therapeutic index, diequatorial (trans 4) isomers were, with one exception, as active as or, in 4 of the 8 examples, somewhat more active than the corresponding axial equatorial (cis 4) isomers. In this series, 4 of the 5 2-fluoroethyl analogues prepared were clearly inferior to the corresponding 2 chloroethyl analogues.
